GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (OTCPK:SHIEF) » Definitions » Equity-to-Asset

SHIEF (Shield Therapeutics) Equity-to-Asset : 0.01 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shield Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Shield Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $0.54 Mil. Shield Therapeutics's Total Assets for the quarter that ended in Jun. 2024 was $46.76 Mil. Therefore, Shield Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.01.

The historical rank and industry rank for Shield Therapeutics's Equity-to-Asset or its related term are showing as below:

SHIEF' s Equity-to-Asset Range Over the Past 10 Years
Min: -19.94   Med: 0.92   Max: 0.97
Current: 0.01

During the past 10 years, the highest Equity to Asset Ratio of Shield Therapeutics was 0.97. The lowest was -19.94. And the median was 0.92.

SHIEF's Equity-to-Asset is ranked worse than
89.92% of 1042 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs SHIEF: 0.01

Shield Therapeutics Equity-to-Asset Historical Data

The historical data trend for Shield Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Equity-to-Asset Chart

Shield Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.93 0.92 0.25 0.31

Shield Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.25 0.65 0.31 0.01

Competitive Comparison of Shield Therapeutics's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shield Therapeutics's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Equity-to-Asset falls into.



Shield Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Shield Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=15.033/48.799
=0.31

Shield Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=0.541/46.761
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shield Therapeutics  (OTCPK:SHIEF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Shield Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Shield Therapeutics Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.

Shield Therapeutics Headlines